Seeing Is Believing
Currently out of the existing stock ratings of Mani Foroohar, 118 are a BUY (53.64%), 87 are a HOLD (39.55%), 15 are a SELL (6.82%).
Analyst Mani Foroohar, currently employed at LEERINK, carries an average stock price target met ratio of 49.83% that have a potential upside of 42.9% achieved within 196 days.
Mani Foroohar’s has documented 401 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BBIO, BridgeBio Pharma at 17-Oct-2024.
Analyst best performing recommendations are on FDMT (4D MOLECULAR THERAPEUTICS ).
The best stock recommendation documented was for FDMT (4D MOLECULAR THERAPEUTICS ) at 11/14/2022. The price target of $15 was fulfilled within 1 day with a profit of $1.51 (11.19%) receiving and performance score of 111.93.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$12
$4.59 (61.94%)
$30
2 months 26 days ago
(13-Aug-2024)
1/5 (20%)
$5.24 (77.51%)
35
Buy
$30
$22.59 (304.86%)
$30
2 months 26 days ago
(13-Aug-2024)
0/3 (0%)
$23.24 (343.79%)
Buy
$40
$32.59 (439.81%)
$4
3 months 21 days ago
(18-Jul-2024)
1/4 (25%)
$30.52 (321.94%)
543
Buy
$22
$14.59 (196.90%)
$40
6 months 10 days ago
(29-Apr-2024)
2/5 (40%)
$12.47 (130.85%)
52
Buy
$6
$4.05 (207.69%)
$4
1 years 2 months 3 days ago
(05-Sep-2023)
4/7 (57.14%)
$4.22 (237.08%)
196
Which stock is Mani Foroohar is most bullish on?
Which stock is Mani Foroohar is most reserved on?
What Year was the first public recommendation made by Mani Foroohar?